Research films > REALITY trial > REALITY (full length)

The REALITY Trial – Saving the lives of those who seek HIV treatment very late (full length)

How to you keep those who seek HIV treatment when they are already very sick, or when their immune system is badly damaged, alive long enough for Anti-Retroviral Therapy (ART) to kick in? Around a quarter of patients in sub-Saharan Africa present late. Of these, 10% die within the first three months on treatment with ART. Late presenters are where most HIV related deaths occur. The REALITY trial found that this mortality rate could be reduced by 27% with the use of a package of cheap and easily available anti-microbial medicines during the first three months of treatment. The study also highlights reasons why so many people seek treatment late. It suggests that community perceptions of HIV are still dominated by fear and key messages about the effectiveness of HIV treatment are poorly understood.

0 Comments

Submit a Comment

Your comments provide extremely useful feedback about what we are doing well and how we could make films better. Please note that we check all comments against our publication standards before approving them.

Watch this film on one of our video channels:     

Download this film to watch and share offline: Visit our downloads page

Want to stay updated about our future projects? Register for our newsletter

If you are using our films for education or training through an organisation which has a budget, we request that you make a donation. Visit our Donate page to see our suggested contribution amounts:

Sign up for our free newsletter

By signing up to our mailing list, you agree to allow Picturing Health to email you regularly with film projects, news and appeals relating to our work. We will not share your information and you can opt out any time.

Thank you for subscribing

Sign up for our free newsletter

By signing up to our mailing list, you agree to allow Picturing Health to email you regularly with film projects, news and appeals relating to our work. We will not share your information and you can opt out any time.

Thank you for subscribing